Amplia Therapeutics Limited, a pharmaceutical company, focuses on advancing a pipeline of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. Its clinical development pipeline comprises two lead molecules, AMP945 and AMP886 that inhibits FAK. The company also manufactures and sells drugs. The company was formerly known as Innate Immunotherapeutics Limited and changed its name to Amplia Therapeutics Limited in September 2018. Amplia Therapeutics Limited was incorporated in 2000 and is headquartered in North Melbourne, Australia.
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone61 2 8003 3650
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$50,474.00
Profitability
Miscellaneous
EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable
Amplia Therapeutics (ASX:ATX) Frequently Asked Questions
What is Amplia Therapeutics' stock symbol?
Amplia Therapeutics trades on the ASX under the ticker symbol "ATX."
Has Amplia Therapeutics been receiving favorable news coverage?
News coverage about ATX stock has been trending somewhat positive this week, according to InfoTrie. InfoTrie rates the sentiment of press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Amplia Therapeutics earned a media sentiment score of 0.8 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the near future. View News Stories for Amplia Therapeutics.
Who are some of Amplia Therapeutics' key competitors?
Some companies that are related to Amplia Therapeutics include ImmuPharma (IMM), Cellmid (CDY), Oncolytics Biotech (ONC), NovaBay Pharmaceuticals (NBY), Collagen Solutions (COS), Suda Pharmaceuticals (SUD), iCo Therapeutics (ICO), Fusion Antibodies (FAB), Race Oncology (RAC), Realm Therapeutics (RLM), Hvivo (HVO), Bioxyne (BXN), biOasis Technologies (BTI), Devonian Health Group (GSD) and Kane Biotech (KNE).
Who are Amplia Therapeutics' key executives?
Amplia Therapeutics' management team includes the folowing people:
- Dr. John Lambert, Chief Exec. Officer
- Mr. Jeff Carter MAppFin, BFinAdmin, Chief Financial Officer (Age 61)
- Mr. Andrew J. Cooke L.L.B., LLB, FAICS, MAICD, FGIA, FCIS, Company Sec. & Independent Non-Exec. Director (Age 59)
- Mark Devlin, Chief Scientific Advisor
- Dr. Frank Gelder, Founding Scientist
How big of a company is Amplia Therapeutics?
What is Amplia Therapeutics' official website?
How can I contact Amplia Therapeutics?
The company can be reached via phone at 61 2 8003 3650.
MarketBeat Community Rating for Amplia Therapeutics (ASX ATX)
MarketBeat's community ratings are surveys of what our community members think about Amplia Therapeutics and other stocks. Vote "Outperform" if you believe ATX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ATX will underperform the S&P 500 over the long term. You may vote once every thirty days.
